For more than a decade, the International Myeloma Foundation has attended the American Society of Hematology (ASH) annual meeting, an exciting convergence of more than 30,000 health-care professionals from around the world. Explore this page to learn about the latest blood cancer research from the meeting, especially key clinical trials to advance the treatment and management of multiple myeloma
IMF brings patients that are support group leaders to ASH to share their perspective.
Of the 4,140 abstracts presented at the 2021 ASH meeting, 879 were multiple myeloma-related. In this "Best of ASH 2021" webinar, IMF Chairman of the Board Dr. Brian G.M. Durie highlights the top myeloma abstracts presented during the annual conference
Leading myeloma experts discuss the latest drug therapy news from the annual American Society of Hematology (ASH) conference.
Live symposium featuring discussion of patient case studies and key clinical trial data by renowned clinical experts providing their perspectives on recent advances in the treatment of multiple myeloma.
IMF Chief Medical Officer Dr. Joseph Mikhael (TGen, City of Hope — Phoenix) talks about abstracts on racial disparities in myeloma care as reported from this year’s American Society of Hematology (ASH) annual conference held in Atlanta, GA.
Quick 5 minute interviews from myeloma specialists at ASH on key abstracts, top 10 lists and summaries.